Zura Bio Limited
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 … Read more
Zura Bio Limited (94E) - Total Liabilities
Latest total liabilities as of September 2025: €25.49 Million EUR
Based on the latest financial reports, Zura Bio Limited (94E) has total liabilities worth €25.49 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zura Bio Limited - Total Liabilities Trend (2021–2024)
This chart illustrates how Zura Bio Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Zura Bio Limited Competitors by Total Liabilities
The table below lists competitors of Zura Bio Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hunan Tyen Machinery Co Ltd B
SHG:900946
|
China | $422.21 Million |
|
ACG Metals Limited
PINK:ACGAF
|
USA | $305.14 Million |
|
Shanghai Huide Science & Technology Co Ltd
SHG:603192
|
China | CN¥682.27 Million |
|
Shanghai Menon Animal Nutrition Technology Co. Ltd.
SHE:301156
|
China | CN¥57.42 Million |
|
Audinate Group Ltd
AU:AD8
|
Australia | AU$17.09 Million |
|
91App Inc
TWO:6741
|
Taiwan | NT$1.44 Billion |
|
Copper 360 Ltd
JSE:CPR
|
South Africa | R1.14 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down Zura Bio Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zura Bio Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zura Bio Limited (2021–2024)
The table below shows the annual total liabilities of Zura Bio Limited from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €19.51 Million | -8.35% |
| 2023-12-31 | €21.29 Million | +43.69% |
| 2022-12-31 | €14.82 Million | +37894.87% |
| 2021-12-31 | €39.00K | -- |